What is the recommended diagnosis and treatment for a giant cell tumor of the spine?

Giant Cell Tumor of the Spine: Diagnosis and Treatment

Surgery with en bloc resection is the gold standard treatment for giant cell tumor of the spine, achieving the lowest recurrence rates, but denosumab is the standard treatment when surgery is unresectable or would result in severe morbidity. 1, 2

Diagnosis

Clinical Presentation

Look specifically for:

• Pain (particularly night pain - a red flag requiring urgent investigation)
• Neurological symptoms including spinal cord compression
• Pathological fracture at presentation 1
• Symptoms typically present for ~3 months before diagnosis, though many present later

Diagnostic Workup

1. Serum calcium levels - mandatory to exclude brown tumors of hyperparathyroidism 1
2. Imaging sequence:
   • Plain radiographs of affected site (initial)
   • MRI or CT of primary site
   • Chest CT to evaluate for metastases (5% metastasize to lungs, particularly after local recurrence) 1
3. Histopathology confirmation:
   • Mononuclear stromal cells with numerous multinucleated giant cells (osteoclasts)
   • H3F3A gene mutation detection - helps distinguish from giant-cell enriched osteosarcoma 1

Key Diagnostic Pitfall

GCTBs are rare before epiphyseal closure - be cautious diagnosing in skeletally immature patients 1

Treatment Algorithm

Step 1: Assess Resectability and Surgical Morbidity

If resectable with acceptable morbidity:

• En bloc excision is preferred over intralesional curettage (lower recurrence rates) 1, 2
• For spinal GCT specifically, complete en bloc spondylectomy remains the gold standard with lowest published recurrence rates 3
• If curettage is chosen for joint/function preservation, use surgical adjuvants (high-speed burring, cement, cryotherapy) to improve local control 1

If unresectable or surgery would cause severe morbidity:

• Denosumab is standard treatment 1, 2

Step 2: Denosumab Protocol

Dosing regimen:

• Three loading doses at weekly intervals (Days 1,8,15)
• Then monthly subcutaneous injections of 120 mg 1, 4
• Mandatory daily supplements: calcium 500 mg + vitamin D 400 IU 1, 5

Expected response:

• 86% tumor response rate (near complete elimination of giant cells or radiological stabilization at 6 months) 1
• Rapid pain reduction and functional improvement in most patients 1
• Response typically shows rapid changes on PET scan within 28 days 1

Duration considerations:

• Optimal duration unclear, but 6 months reasonable for responding tumors if surgery planned 1
• For inoperable tumors, may require life-long treatment 1
• Critical warning: Most tumors recur ~9 months after stopping denosumab, so surgical resection indicated where possible 1
• For stable disease at 2 years, interval may be extended from 4-weekly to 8-weekly 1

Step 3: Neoadjuvant Denosumab Strategy

Consider preoperative denosumab (3-24 months) to:

• Solidify soft tissue component
• Facilitate surgical resection
• Reduce recurrence risk 1, 4

Important caveat: Curettage after denosumab is difficult and associated with higher risk of local recurrence 1. Therefore, complete resection is preferred after denosumab treatment rather than curettage 1.

Step 4: Radiotherapy

Indications:

• Unresectable disease (primary or recurrent)
• After incomplete surgery
• Symptom palliation 1
• Historically used where surgery judged unacceptably morbid, with local control rates approaching 80% 1

Step 5: Management of Metastatic Disease

• Life-long denosumab for patients with metastases 1
• Surgery for pulmonary metastases usually not performed 1

Special Considerations

Malignant Transformation

Rarely, GCTs transform to high-grade tumors. These patients:

• Do not benefit from denosumab 1
• Should receive combination cytotoxic chemotherapy following osteosarcoma protocols 1

Contraindications and Side Effects of Denosumab

• Must avoid pregnancy (adequate contraception required) 1
• Significant side effects: hypocalcemia, osteonecrosis of jaw, atypical fractures 1

Follow-Up Protocol

High-risk features (locally aggressive, 50% recurrence risk, 5% metastasis rate):

• Every 2-4 months for first 3 years
• Every 6 months for years 4-5
• Annually thereafter 1
• Include physical examination, imaging of primary site, and chest surveillance
• No universally accepted stopping point - late recurrences can occur >10 years after diagnosis 1, 2

Management Must Be Through Bone Sarcoma MDT

All patients with GCTB should be managed by a specialized bone sarcoma multidisciplinary team 1. The complexity of spinal anatomy, high recurrence rates (up to 50%), and need for individualized surgical versus medical approaches necessitate expert collaborative decision-making.